Olema Pharmaceuticals, Inc. (OLMA)
9.82
-0.08
(-0.81%)
USD |
NASDAQ |
Sep 18, 16:00
9.82
0.00 (0.00%)
After-Hours: 20:00
Olema Pharmaceuticals Enterprise Value : 401.37M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 401.37M |
| September 17, 2026 | 408.37M |
| September 16, 2026 | 393.50M |
| September 15, 2026 | 397.87M |
| September 14, 2026 | 442.47M |
| September 11, 2026 | 436.35M |
| September 10, 2026 | 477.45M |
| September 09, 2026 | 448.59M |
| September 08, 2026 | 503.25M |
| September 04, 2026 | 482.70M |
| September 03, 2026 | 480.95M |
| September 02, 2026 | 489.70M |
| September 01, 2026 | 466.09M |
| August 31, 2026 | 454.72M |
| August 28, 2026 | 440.72M |
| August 27, 2026 | 486.20M |
| August 26, 2026 | 491.45M |
| August 25, 2026 | 496.69M |
| August 24, 2026 | 454.72M |
| August 21, 2026 | 477.45M |
| August 20, 2026 | 495.82M |
| August 19, 2026 | 531.67M |
| August 18, 2026 | 473.96M |
| August 17, 2026 | 484.45M |
| August 14, 2026 | 472.21M |
| Date | Value |
|---|---|
| August 13, 2026 | 461.71M |
| August 12, 2026 | 455.59M |
| August 11, 2026 | 454.72M |
| August 10, 2026 | 586.77M |
| August 07, 2026 | 596.39M |
| August 06, 2026 | 574.53M |
| August 05, 2026 | 555.29M |
| August 04, 2026 | 571.03M |
| August 03, 2026 | 529.05M |
| July 31, 2026 | 543.92M |
| July 30, 2026 | 576.28M |
| July 29, 2026 | 521.18M |
| July 28, 2026 | 558.78M |
| July 27, 2026 | 592.89M |
| July 24, 2026 | 565.78M |
| July 23, 2026 | 569.28M |
| July 22, 2026 | 547.42M |
| July 21, 2026 | 556.16M |
| July 20, 2026 | 535.17M |
| July 17, 2026 | 545.67M |
| July 16, 2026 | 510.69M |
| July 15, 2026 | 576.28M |
| July 14, 2026 | 578.90M |
| July 13, 2026 | 578.90M |
| July 10, 2026 | 584.15M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| SELLAS Life Sciences Group, Inc. | 2.182B |
| ACADIA Pharmaceuticals, Inc. | 3.815B |
| Alnylam Pharmaceuticals, Inc. | 31.72B |
| Anika Therapeutics, Inc. | 265.34M |
| Savara, Inc. | 960.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -63.20M |
| Total Expenses (Quarterly) | 63.20M |
| EPS Diluted (Quarterly) | -0.605 |
| Earnings Yield | -21.57% |
| Normalized Earnings Yield | -21.57 |